<DOC>
	<DOCNO>NCT01289028</DOCNO>
	<brief_summary>This study evaluate preliminary efficacy nilotinib pretreated patient ( Imatinib , Sunitinib ) unresectable metastatic gastrointestinal stromal tumor .</brief_summary>
	<brief_title>Efficacy Nilotinib Adult Patients With Gastrointestinal Stromal Tumors Resistant Imatinib Sunitinib .</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Histologically confirm diagnosis GIST unresectable and/or metastatic therefore amenable surgery combine modality curative intent . Radiologically confirmed disease progression imatinib therapy dose least 400 mg daily and/or radiologically confirm disease progression sunitinib therapy OR document intolerance imatinib and/or sunitinib . ( Patients prior additional investigational treatment GIST prior study entry include . ) At least one measurable site disease CT/MRI define RECIST criterion . Prior treatment nilotinib . Treatment cytotoxic and/or investigational cytotoxic drug â‰¤ 4 week ( 6 week nitrosurea mitomycin C ) prior Visit 1 . Prior concomitant malignancy require active treatment GIST exception previous concomitant basal cell skin cancer , previous cervical carcinoma situ . Impaired cardiac function visit 1 Patients severe and/or uncontrolled concurrent medical disease opinion investigator could cause unacceptable safety risk compromise compliance protocol e.g . impairment gastrointestinal ( GI ) function , GI disease may significantly alter absorption study drug , uncontrolled diabetes . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>GIST</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Gastrointestinal</keyword>
	<keyword>Stromal</keyword>
	<keyword>Tumors</keyword>
</DOC>